COVID Vaccine Stock: Your Best Chance at Owning the COVID Vaccine Maker
Below, Investment U’s Technical Options Expert, Bryan Bottarelli, takes a look at the best COVID Vaccine Stock available today.
It seems pretty logical…
You want to own the company that’ll manufacture and supply the United States (and perhaps even the world) with the COVID-19 vaccines, right?
The gains could be enormous – especially on the day that this world-changing news gets announced.
But the problem is…
How do you identify and invest in the one COVID vaccine stock that’ll emerge as the winner?
A simple Google search shows that 23 of the world’s largest biotech and pharma companies are actively working on coronavirus treatments or vaccines.
You already know that this group includes Pfizer, Gilead Sciences, Regeneron and Moderna.
Break this down even more and you’ll find a collection of companies making vaccines, treatments and testing kits.
And many of them are smaller biotech companies that you’ve never even heard of.
So again, aside from throwing a dart and hoping that it lands in the bull’s-eye…
How on Earth do you pick a COVID vaccine stock winner? Today, I have that answer for you…
The Best COVID Vaccine Stock Available
It comes in the form of the SPDR S&P Biotech ETF (NYSE: XBI).
Unlike other biotech exchange-traded funds (ETFs), I like the SPDR S&P Biotech ETF because it emphasizes small cap growth.
Its top 10 holdings all represent potential diamonds in the rough that could easily emerge as top COVID-19 candidates in no time.
This list includes:
- Inovio Pharmaceuticals
- Amicus Therapeutics
- Opko Health
- Arrowhead Pharmaceuticals
- Alnylam Pharmaceuticals
- Esperion Therapeutics.
Not familiar with most of these?
You’re not alone. And that’s why I think the SPDR S&P Biotech ETF is such a winner.
Biotech Sector Action Plan
I like the idea of having cheap upside exposure to the biotech sector – especially the smaller, more exciting names in the group. In my view, the very best way to own an entire basket of the most promising biotech stocks on the market today is by owning the SPDR S&P Biotech ETF. Consider adding it to your ledger now!
About Bryan Bottarelli
Whether it was selling the Star Wars figures he collected as a little boy for 50 times their value or using the $125 he made cutting grass to buy a Michael Jordan rookie card that he later sold for $1,500, it was always clear that Bryan Bottarelli was a born trader – possessing the unique ability to identify opportunities and leverage his investments.
Graduating with a business degree from the highly rated Indiana University Kelley School of Business, Bryan got his first job out of college trading stock options on the floor of the Chicago Board Options Exchange (CBOE). There, he was mentored by one of the country’s top floor traders during the heart of the technology boom from 1999 to 2000 – trading in the crowded and lively Apple computer pit. Executing his trades in real time, Bryan learned to identify and implement some of his most powerful trading secrets… secrets that rarely find their way outside the CBOE to be used by individual traders.
Recognizing the true value of these methods, Bryan tapped into his entrepreneurial spirit and took a risk. He walked off the CBOE floor and launched his own independent trading research service called Bottarelli Research. From February 2006 to December 2018, Bryan gave his precise trading instructions to a small, elite group – most of whom have been followers ever since.
As a “play tactician,” Bryan uses his hands-on knowledge of floor trading to shape opportunities and chart formations into elegant, powerful and profitable recommendations. And by using the same hedging techniques taught by professional floor traders, Bryan is able to deliver his readers remarkable gain opportunities while strictly limiting their total risk.
Along the way, Bryan has developed a cumulative track record that could impress even the most successful hedge fund manager.
He now spends his days moderating one of the most elite trading research forums ever created: The War Room.